<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary ciliary dyskinesia (immotile-cilia syndrome)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary ciliary dyskinesia (immotile-cilia syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary ciliary dyskinesia (immotile-cilia syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sten-Erik Bergström, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shailendra Das, DO</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26740018"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary ciliary dyskinesia (PCD, also called the immotile-cilia syndrome) is characterized by congenital impairment of mucociliary clearance (MCC) [<a href="#rid1">1</a>]. The underlying cause is a defect of cilia in the airways, making them unable to beat (ciliary immotility), unable to beat normally (ciliary dyskinesia), or absent altogether (ciliary aplasia). It is an inherited disease that has been described from most parts of the world with equal prevalence in males and females [<a href="#rid1">1-5</a>]. Genomic studies analyzing the frequency of defects in 29 causal genes estimate that PCD affects at least 1 in 7,500 people worldwide, doubling the prior epidemiologic estimates [<a href="#rid6">6</a>]. However, even these studies likely underestimate the true disease prevalence, as over 50 genes are now known to cause PCD [<a href="#rid7">7</a>]. By all accounts, most people with PCD remain undiagnosed.</p><p>The genetics, clinical manifestations, diagnosis, and management of PCD are reviewed here. The evaluation and treatment of bronchiectasis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"</a> and  <a class="medical medical_review" href="/z/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management"</a>.)</p><p class="headingAnchor" id="H1644180040"><span class="h1">CILIARY FUNCTION</span><span class="headingEndMark"> — </span>PCD is a highly heterogeneous syndrome that can be caused by a defect in any of the many polypeptide species within the axoneme (central core) of cilia or of sperm flagella, in other proteins that are present in the ciliary membrane and matrix, or in proteins needed for the proper assembly of cilia [<a href="#rid5">5,8-13</a>]. Different components may be missing or defective in different patients, and different clinical manifestations may develop depending upon the nature of the lesion [<a href="#rid14">14-16</a>].</p><p>Motile cilia in the upper and lower respiratory tract epithelium have microtubules that are composed of alpha and beta monomers of tubulin and a complex axonemal structure of inner and outer dynein arms, radial spokes, and nexin links  (<a class="graphic graphic_diagnosticimage graphicRef96118" href="/z/d/graphic/96118.html" rel="external">image 1</a>). Respiratory epithelial cells have approximately 200 cilia per cell that beat in a coordinated fashion to move respiratory secretions. Mutations in the genes encoding the axonemal structure and accessory components of cilia can result in primary ciliary dyskinesia. Some mutations result in abnormal ultrastructure and others in abnormal function, but preserved ultrastructure.</p><p class="headingAnchor" id="H26740025"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>PCD is most often inherited as an autosomal recessive disease (eg, Mendelian inheritance in man [MIN] 244400), although autosomal dominant (<em>FOXJ1</em>-PCD) and X-linked inheritance (<em>PIH1D3</em>-PCD) have been reported [<a href="#rid17">17-20</a>]. More than 50 different PCD-causing genetic variants have been described, including mutations in the axonemal outer dynein arms (<em>DNAH5, DNAH9, DNAH12, DNAI1, DNAL1, ARMC4, CCDC103</em>), inner dynein arms (<em>DNALI1</em>), assembly proteins (<em>DNAAF3</em>), and radial spokes (<em>RSPH4A, RSPH9</em>)  (<a class="graphic graphic_diagnosticimage graphicRef96118" href="/z/d/graphic/96118.html" rel="external">image 1</a> and <a class="graphic graphic_figure graphicRef128205" href="/z/d/graphic/128205.html" rel="external">figure 1</a>) [<a href="#rid21">21-31</a>]. Families may have different mutated genes, but identical clinical symptoms.</p><p>In some cases it has been possible to identify a specific chromosomal locus and gene product [<a href="#rid32">32,33</a>]. As an example, in patients with PCD, a mutation of <em>DNAH5</em> on chromosome 5p15 is reported to be disease-causing in 28 percent and present in 53 percent of unrelated patients with associated partial or total loss of outer dynein arms [<a href="#rid34">34</a>]. Complete absence of <em>DNAH5</em> along the ciliary axoneme results in immobility, while absence of <em>DNAH5</em> in the distal portion of the axoneme causes impaired mobility [<a href="#rid35">35</a>].</p><p>A number of other genes are associated with PCD, including the dynein arm genes <em>DNAI1</em>, which encodes the outer dynein arm intermediate chain, and <em>DNAH11</em>, which is associated with normal-appearing dynein arms but impaired function [<a href="#rid36">36-40</a>]. Radial spoke head gene mutations (eg, <em>RSPH4A, RSPH9</em>) have been identified and appear to be associated with PCD, but not situs inversus [<a href="#rid41">41</a>]. Mutations in <em>DNAI1</em> and <em>DNAH5</em> are present in approximately 30 to 38 percent of families with PCD [<a href="#rid42">42</a>].</p><p>The trait of situs inversus apparently has an element of random determination [<a href="#rid1">1,43</a>]. Rather than having one gene for situs solitus (organs in their normal position) and one for situs inversus, the nodal cilia of the embryo are responsible for controlling the normal position of heart and visceral organs, and without such control there is an equal chance of situs inversus and situs solitus. Two pairs of monozygotic twins with primary ciliary dyskinesia have been identified; in each pair there was one twin with situs inversus and one with situs solitus [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H26740032"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Considerable variation exists in the clinical presentation of primary ciliary dyskinesia (PCD), although the most common features are recurrent infections of the upper and lower respiratory tract [<a href="#rid29">29,45-47</a>]. Most patients with PCD present in childhood (median age of diagnosis 5 to 5.5 years), but some present in adulthood (median age of diagnosis 22 years) [<a href="#rid4">4,48,49</a>]. Among adults, the age at diagnosis varies; in a series from Cyprus, the median age at presentation was 36.3 years (range 23.4 to 58.4) [<a href="#rid49">49</a>], while in a North American population, the median age at diagnosis was 22 years [<a href="#rid4">4</a>].</p><p>Because the embryonic, nodal cilia can also be defective, body asymmetry occurs randomly so that approximately 50 percent of the patients have situs inversus totalis  (<a class="graphic graphic_diagnosticimage graphicRef89096" href="/z/d/graphic/89096.html" rel="external">image 2</a>) [<a href="#rid48">48,50,51</a>]. When situs inversus, chronic sinusitis, and bronchiectasis occur together, an individual is said to have Kartagener syndrome.</p><p class="headingAnchor" id="H26740039"><span class="h2">Pulmonary</span><span class="headingEndMark"> — </span>Newborns with primary ciliary dyskinesia often suffer from mild respiratory distress, such as tachypnea or mild hypoxemia, and may require supplemental oxygen for a few hours to days after birth [<a href="#rid4">4,24,29,52-54</a>]. Respiratory symptoms complicate the first month of life in 60 percent of patients with PCD [<a href="#rid55">55</a>]. The great majority of adults and children with primary ciliary dyskinesia have a chronic productive cough [<a href="#rid56">56,57</a>]. Recurrent pneumonias are also common and were reported by approximately 75 percent of patients in a PCD registry [<a href="#rid55">55,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/5066.html" rel="external">"Transient tachypnea of the newborn", section on 'Diagnosis'</a>.)</p><p>Patients with bronchiectasis generally manifest auscultatory crackles and may have wheezes that mimic asthma, particularly in children. In one series, clubbing was not seen in children but was seen in 8 percent of adults [<a href="#rid49">49</a>].</p><p>Common findings on chest radiograph and high resolution computed tomography (HRCT) include a moderate degree of hyperinflation, peribronchial thickening, atelectasis, mucus plugging or impaction, and bronchiectasis  (<a class="graphic graphic_diagnosticimage graphicRef89096" href="/z/d/graphic/89096.html" rel="external">image 2</a> and <a class="graphic graphic_diagnosticimage graphicRef54505 graphicRef70358" href="/z/d/graphic/54505.html" rel="external">image 3A-B</a>) [<a href="#rid58">58</a>]. Cylindrical or saccular bronchiectasis may occur, even in childhood, and usually affects the middle and lower lobes and the lingula [<a href="#rid59">59</a>]. Bronchiectasis is reported to be present on HRCT in all adults and approximately 50 percent of children [<a href="#rid60">60</a>]. Multiple, diffuse small centrilobular nodules up to 2 mm are sometimes seen, probably representing bronchiolitis [<a href="#rid61">61</a>].</p><p>Spirometry often reveals mild to moderate airway obstruction with variable responsiveness to bronchodilators [<a href="#rid62">62,63</a>]. However, in contrast to patients with cystic fibrosis, forced expiratory volume in one second (FEV<sub>1</sub>) does not necessarily correlate with HRCT findings [<a href="#rid64">64</a>].</p><p>Sputum cultures have demonstrated the major infecting bacteria are <em>Haemophilus influenzae</em>, <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, <em>Pseudomonas aeruginosa</em>,<em> </em>or nontuberculous mycobacteria [<a href="#rid51">51</a>]. Mucoid <em>P. aeruginosa</em> tends to appear after age 30, which is delayed compared with cystic fibrosis.</p><p class="headingAnchor" id="H26740046"><span class="h2">Rhinosinusitis</span><span class="headingEndMark"> — </span>A constant, non-seasonal runny nose and year-round nasal congestion may be noted beginning in early childhood [<a href="#rid42">42,65</a>]. Uncomplicated common colds do not seem to occur more often in PCD than in normal subjects, nor do they usually have a more severe course. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3412.html" rel="external">"Microbiology and antibiotic management of chronic rhinosinusitis"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>Rhinosinusitis is a cardinal feature of PCD, occurring in almost 100 percent of affected individuals [<a href="#rid66">66</a>]. Nasal polyposis is frequently present; chronic sinusitis typically involves the maxillary  (<a class="graphic graphic_diagnosticimage graphicRef89096" href="/z/d/graphic/89096.html" rel="external">image 2</a>) and ethmoidal sinuses, while the frontal and sphenoid sinuses are less likely affected as they often fail to develop [<a href="#rid67">67-69</a>]. The absence of a frontal sinus often gives the voice a somewhat nasal tone.</p><p>A sinus CT scan is usually obtained to assess for chronic sinusitis in patients with persistent mucopurulent drainage (anterior and/or posterior), nasal obstruction or blockage, and facial pain or pressure [<a href="#rid70">70</a>]. In adults, impaired or absent sense of smell is another clue to the presence of chronic rhinosinusitis, while a chronic cough is a more common clue in children.</p><p class="headingAnchor" id="H26740053"><span class="h2">Otitis</span><span class="headingEndMark"> — </span>The otologic complications of PCD are a consequence of defective ciliary function in the Eustachian tube and middle ear cleft, leading to poor mucociliary clearance. Chronic otitis media with effusion (serous otitis media) and recurrent episodes of acute otitis media are common during childhood and adolescence, but these problems become much less frequent following puberty [<a href="#rid42">42,65,68,71</a>]. Conductive hearing loss is common [<a href="#rid4">4,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/6872.html" rel="external">"Acute otitis media in adults", section on 'Immune dysfunction'</a> and  <a class="medical medical_review" href="/z/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment", section on 'Recurrent episode of AOM'</a>.)</p><p class="headingAnchor" id="H26740060"><span class="h2">Situs inversus and Kartagener syndrome</span><span class="headingEndMark"> — </span>Situs inversus, when present in patients with primary ciliary dyskinesia, generally occurs as a complete reversal of the circulatory system and the viscera known as situs inversus totalis  (<a class="graphic graphic_diagnosticimage graphicRef89096" href="/z/d/graphic/89096.html" rel="external">image 2</a>). Situs inversus has no serious adverse health consequences per se, and the condition often goes undetected until a chest radiograph is obtained. Situs inversus is a very useful sign when primary ciliary dyskinesia is being considered, but as described above, is present only in approximately 50 percent of patients with primary ciliary dyskinesia. However, most individuals with situs inversus do not have PCD [<a href="#rid73">73</a>]. Isolated situs inversus has a prevalence of about 1 in 10,000 in Scandinavia [<a href="#rid74">74</a>].</p><p>When situs inversus, chronic sinusitis, and bronchiectasis occur together, an individual is said to have Kartagener syndrome, which is a subgroup of primary ciliary dyskinesia that has a prevalence of around 1 in 20,000 to 40,000 individuals [<a href="#rid3">3</a>]. Bronchiectasis may develop in young persons, but it is never present at birth; thus, no individual is born with a fully developed Kartagener triad.</p><p class="headingAnchor" id="H26740067"><span class="h2">Central nervous system</span><span class="headingEndMark"> — </span>Fatigue and headaches are common complaints and may be caused by chronic sinusitis, although the headaches may persist even during infection-free periods. </p><p>Hydrocephalus has been described from several persons with primary ciliary dyskinesia and two siblings with ciliary aplasia [<a href="#rid18">18,75-79</a>]. Impaired function of ependymal cilia that line the ventricles of the brain may be at least partially responsible [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H26740074"><span class="h2">Fertility</span><span class="headingEndMark"> — </span>Most males with PCD have living but immotile spermatozoa and are infertile, although some have motile spermatozoa but immotile cilia and others are azoospermic [<a href="#rid4">4,81,82</a>]. Female patients with PCD likewise have decreased fertility, with fewer than 50 percent successfully completing pregnancy [<a href="#rid2">2,83</a>]. Impaired ciliary function in the fallopian tubules can delay ovum transit leading to reduced fertility or, on very rare occasions, ectopic pregnancy [<a href="#rid4">4</a>]. Specialty fertility care is underutilized and is appropriate for adults with PCD [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H26740081"><span class="h2">Associated abnormalities</span><span class="headingEndMark"> — </span>A number of other congenital abnormalities are occasionally associated with primary ciliary dyskinesia, including transposition of the great vessels and other cardiac abnormalities, pyloric stenosis, and epispadias [<a href="#rid29">29</a>]. Cardiac evaluation is suggested for most patients since the incidence of congenital heart disease with heterotaxy is reported to be 200-fold higher in PCD than the general population [<a href="#rid85">85,86</a>]. (See  <a class="medical medical_review" href="/z/d/html/83229.html" rel="external">"L-transposition of the great arteries (L-TGA): Anatomy, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5890.html" rel="external">"Infantile hypertrophic pyloric stenosis"</a> and  <a class="medical medical_review" href="/z/d/html/14557.html" rel="external">"Heterotaxy (isomerism of the atrial appendages): Anatomy, clinical features, and diagnosis"</a>.)</p><p>Among patients with PCD, the frequencies of pectus excavatum (10 percent) and scoliosis (5 to 10 percent) are increased [<a href="#rid4">4,60,87</a>].</p><p>Both aerobic and anaerobic performance are often impaired from early age [<a href="#rid63">63,88,89</a>]. One-third of PCD patients aged 6 to 29 years are reported to exhibit substantially lower aerobic fitness compared with healthy controls [<a href="#rid90">90</a>].</p><p>Concurrence of humoral immunodeficiency (eg, immunoglobulin [Ig] G, IgG subclass, IgM, and IgA) and PCD has been reported in 6 percent of patients with PCD [<a href="#rid91">91</a>]. The mechanism of the association and potential contribution to recurrent sinopulmonary infections have not been fully studied.</p><p class="headingAnchor" id="H26740088"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The crucial diagnostic feature of primary ciliary dyskinesia is an inborn error of the cilia, rendering them immotile, dysmotile, or missing. However, no "gold standard" diagnostic test has been established. In the absence of cystic fibrosis or prematurity, a history of neonatal respiratory distress (tachycardia, cough, pneumonia), early onset and persistent cough, chronic nasal congestion and rhinorrhea, chronic otitis media, and a laterality defect (eg, situs inversus or ambiguous) should raise a strong clinical suspicion for PCD [<a href="#rid28">28</a>]. In adults, PCD should be suspected in males with dyskinetic spermatozoa and respiratory symptoms and in females who are infertile or subfertile without other explanation, particularly in the presence of respiratory symptoms. </p><p>The PICADAR score may be a useful algorithm when evaluating clinical manifestations and determining the need for further diagnostic testing in patients with a productive cough  (<a class="graphic graphic_table graphicRef132458" href="/z/d/graphic/132458.html" rel="external">table 1</a>) [<a href="#rid92">92</a>]. </p><p>A number of tests have been employed and each has advantages and disadvantages  (<a class="graphic graphic_table graphicRef77133" href="/z/d/graphic/77133.html" rel="external">table 2</a>) [<a href="#rid5">5,24,65,93,94</a>]. A combination of tests is necessary for accurate diagnosis of PCD, as described in the guidelines published by the European Respiratory Society  (<a class="graphic graphic_algorithm graphicRef114172" href="/z/d/graphic/114172.html" rel="external">algorithm 1</a>) [<a href="#rid28">28,94,95</a>].</p><p>Tests measuring nasal nitric oxide and mucociliary clearance may be useful for screening but generally require confirmation with tests of ciliary function and ultrastructure [<a href="#rid65">65</a>]. The role of genetic testing is changing with the identification of a greater number of PCD-causing mutations and development of high-throughput testing. Referral to a specialist (eg, pediatric or adult pulmonary) is generally necessary for diagnostic evaluation.</p><p class="headingAnchor" id="H26740095"><span class="h2">Nasal nitric oxide</span><span class="headingEndMark"> — </span>Measuring the amount of nasal nitric oxide (nNO), which is very low or absent in patients with PCD, is a useful screening test for patients age five years or older with a clinical suspicion of PCD [<a href="#rid28">28,95-104</a>]. In this age group, a threshold of 77 nL/min is the standard cutoff when nNO is measured using exhalation against resistance or breathhold maneuvers [<a href="#rid105">105,106</a>]. Other cutoffs may be appropriate for younger children or measurements during tidal breathing.</p><p>Studies supporting this cutoff include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 143 patients with PCD, 146 subjects with other respiratory diseases, and 78 healthy controls, nNO accurately identified patients with PCD, although some overlap with cystic fibrosis (CF) was noted [<a href="#rid101">101</a>]. An nNO ≥77 nL/minute was determined as a cutoff value that excludes PCD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 301 patients without CF referred for possible PCD also found that the 77nl/min cutoff was near-optimal, with a sensitivity of 92 percent and specificity of 86 percent based on subsequent testing [<a href="#rid107">107</a>].</p><p></p><p>Following nNO measurement, confirmatory testing (eg, ultrastructural studies, sweat test, cystic fibrosis and PCD genetic studies) is required because other respiratory conditions, such as cystic fibrosis and acute viral infection, may rarely present with low nNO [<a href="#rid108">108</a>]. Certain genetic variants (eg, radial spoke head proteins) and some genotypes with dyskinetic, but motile, cilia are also associated with normal nNO levels, so other testing is needed to make the diagnosis of PCD in these cases [<a href="#rid28">28,109</a>]. On the other hand, nNO may be particularly helpful in atypical PCD phenotypes with normal ciliary ultrastructure, but abnormal function [<a href="#rid4">4,94,110</a>]. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications", section on 'Formation of NO'</a>.)</p><p>The technique requires modification of the apparatus and procedure used for measuring exhaled nitric oxide in asthma. It is important to conduct the measurements when there is no recent acute nasal or respiratory infection. To obtain accurate measurements, nNO is measured from the nose during velum closure. Velum closure can be achieved by exhaling against resistance or into a party toy, which reduces dilution from the lower airways [<a href="#rid101">101,102,105,106</a>].</p><p>In patients who cannot perform the velum closure maneuver, an alternative approach is to hold their breath with glottis closure and perform a valsalva maneuver. Although this method is somewhat less reliable, it can still provide an acceptable reading.</p><p>For real-time feedback of nNO plateaus, it is best to measure nNO by chemiluminescence devices during one of these maneuvers. The nNO production (nL/min) is calculated by multiplying the nNO plateau concentration (in parts per billion) by the sampling flow rate, which varies according to the chemiluminescent analyzer used.</p><p>Portable electrochemical analyzers may also be used with similar technique and interpretation, but the results are generally less consistent or reliable, and the equipment has not yet been as well-validated [<a href="#rid105">105</a>].</p><p>The reduced levels of nasal NO in patients with PCD may be related to alterations in nasal nitric oxide synthetase (NOS) activity, increased consumption of NO by superoxide anions, obstruction of the paranasal sinuses inhibiting release of NO into the nasal passages, or hypoplasia or agenesis of the paranasal sinuses reducing NO production [<a href="#rid110">110</a>]. Gene expression studies in nasal biopsy samples from patients with PCD found reduced mRNA levels of the inducible isoform NOS2, which localizes to the apical part of nasal epithelial cells, compared with patients with secondary ciliary dysfunction [<a href="#rid111">111</a>]. NOS2 gene expression in these biopsies correlated with nasal NO levels. Gene expression of the endothelial isoform NOS3, which is associated with the ciliary basal microtubule membrane, was not reduced. In contrast, a separate report confirmed low levels of NO in nasal and exhaled breath condensates of 15 children with PCD, but found the level of breakdown products (including nitrite) was not low, suggesting that overall NOS activity is not diminished [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H26740109"><span class="h2">Ciliary motion and ultrastructure</span><span class="headingEndMark"> — </span>High speed videomicroscopy analysis (HSVA, also called HSVM) and transmission electron microscopy (TEM) are traditional methods to examine ciliary movement and ultrastructure. The European Respiratory Society guidelines for patients with clinical features of PCD suggest performing HSVA first and proceeding to TEM, if HSVA is abnormal or equivocal [<a href="#rid28">28</a>]. While accurate for patients with complete immotility or gross dysmotility, HSVA requires an experienced videomicroscopist to identify subtle abnormalities of ciliary motion and is not sufficiently diagnostic to be used without additional testing (eg, TEM or extended genetic panel testing) [<a href="#rid4">4,95</a>]. TEM is limited by the need for an adequate sample size and experienced readers [<a href="#rid4">4</a>].</p><p>Samples should be obtained at a time remote from acute nasal or respiratory infection (eg, four to six weeks after infection) [<a href="#rid65">65,113,114</a>]. In a prospective study of 654 patients referred for evaluation of possible PCD, HSVA had a sensitivity and specificity of 100 and 93 percent, respectively [<a href="#rid94">94</a>]. TEM was 100 percent specific but lacked sensitivity in that 21 percent of PCD patients had normal ultrastructure. Combination testing with HSVA and TEM was found to be a highly accurate (100 percent sensitive and 92 percent specific) but this was not recommended until better standardization of testing between centers is achieved.</p><p>Nasal brushing with a bronchoscopy (or similar) brush is the preferred method to obtain ciliate epithelium as it is less invasive; the inferior turbinate is brushed for two to three seconds [<a href="#rid65">65</a>]. Flexible bronchoscopy with bronchial brushing and/or biopsy is performed if the nasal sample is not adequate. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High speed videomicroscopy analysis</strong> – For HSVA, the respiratory epithelial cells are rapidly transferred to an isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solution and examined in the living state. HSVA with beat frequency measurement is used to determine whether cilia have normal coordination, beat frequency, and beat pattern. Slowing ciliary motion by cooling the specimen may help reveal abnormal waveforms [<a href="#rid4">4,115</a>]. For equivocal or abnormal results, repeating the ciliary beat frequency and pattern assessment after air-liquid interface culture improves the accuracy of HSVA [<a href="#rid28">28,116</a>]. The clinical usefulness of these tests has increased, as their accuracy in distinguishing between primary and secondary ciliary dyskinesia has improved [<a href="#rid94">94,115,117,118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission electron microscopy</strong> – TEM analysis is usually performed when the diagnosis is uncertain after high speed video microscopy or genetic testing but may also be performed to identify the type of ciliary abnormality [<a href="#rid65">65,108,119,120</a>]. If a child suspected of PCD is sedated for another reason (eg, tympanostomy, bronchoscopy), a simultaneous brushing or biopsy of nasal or bronchial mucosa is advisable to obtain respiratory cilia for TEM analysis.</p><p></p><p class="bulletIndent1">TEM can be diagnostic if hallmark ciliary ultrastructural defects are identified  (<a class="graphic graphic_figure graphicRef128205" href="/z/d/graphic/128205.html" rel="external">figure 1</a>) [<a href="#rid28">28</a>]. However, TEM can be normal in approximately 20 to 30 percent of patients with PCD, so TEM should not be relied upon as a single diagnostic test [<a href="#rid28">28,120</a>]. An international consensus guideline has defined Class 1 defects (diagnostic of PCD) and Class 2 defects (diagnostic of PCD when accompanied by supporting evidence [eg, HSVA, genetic analysis])  (<a class="graphic graphic_table graphicRef128206" href="/z/d/graphic/128206.html" rel="external">table 3</a>) [<a href="#rid120">120</a>]. The guideline also describes the features that should be mentioned in a TEM report of ciliary ultrastructure, such as source of the sample, number of cross sections assessed, percentage of abnormal cilia with defects, consistency of defect across several cells, and a one-sentence summary of the specific findings. The parameters of an adequate diagnostic sample (eg, review of more than 50 axonemes with intact membranes in cross section) were also addressed in the guideline.</p><p></p><p class="bulletIndent1">For electron microscopy, the fresh biopsy is immersed in a glutaraldehyde solution and further processed for ultrastructural investigation. A commonly observed ultrastructural defect is the absence of so-called dynein arms (dyneins are the high molecular weight motor proteins responsible for ciliary motility); other reported ultrastructural abnormalities include the absence of radial spokes and absent, or additional, microtubule assemblies  (<a class="graphic graphic_figure graphicRef128205" href="/z/d/graphic/128205.html" rel="external">figure 1</a>). A variant form of ciliary transposition, which results in circular ciliary beating and central microtubule agenesis, has also been described [<a href="#rid121">121</a>]. (See <a class="local">'Ciliary function'</a> above.)</p><p></p><p class="bulletIndent1">When the living cilia are seen to be immotile but the ciliary ultrastructure appears quite normal (10 to 20 percent of cases), the underlying defect is likely in membrane pumps or in other proteins not visible in electron micrographs. Use of computer-based image processing algorithms can improve visualization of ultrastructural abnormalities detected using electron microscopy [<a href="#rid122">122</a>].</p><p></p><p class="headingAnchor" id="H26740116"><span class="h2">Cell culture</span><span class="headingEndMark"> — </span>Cell culture is used to allow redifferentiation of ciliated epithelial cells to reduce false positive tests that mistake secondary loss or dysfunction of cilia for PCD [<a href="#rid65">65,113,115,123</a>]. This technique is also useful to confirm the presence of less common phenotypes, such as ciliary disorientation, ciliary aplasia, central microtubular agenesis, and inner dynein arm defects.</p><p>Epithelia from the inferior concha of the nose are obtained with a cytology brush (such as those used for endobronchial brushing during bronchoscopy) and maintained in tissue culture with antibiotics (to eliminate any epithelial bacteria) for several weeks. The culture medium is then supplemented with pronase (to separate the individual cells from the epithelium). After several days, cilia are shed and new ones emerge. Healthy cilia are then recognized by their ability to rotate the cells in the tissue medium, whereas the cells will not rotate if primary ciliary dyskinesia is present. </p><p class="headingAnchor" id="H26740123"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>In a patient with compatible clinical features, a biallelic (or X-linked) pathogenic mutation in a known PCD gene confirms the diagnosis [<a href="#rid28">28,95,124</a>]. Previously, genetic testing for PCD mutations was reserved for patients with normal or equivocal HSVA and TEM and a strongly suggestive history, due to the limited availability of testing and relatively small number of genes in the standard genetic panel (≤12 genes) [<a href="#rid28">28,125</a>]. However, the role of genetic testing for PCD diagnosis is evolving with the increasing availability of extended panel tests and/or whole exome sequencing [<a href="#rid95">95,126</a>]. The 2018 American Thoracic Society as well as the European Respiratory Society guidelines advise use of extended panel genetic testing over TEM ciliary testing and/or standard genetic panel testing for PCD diagnosis [<a href="#rid28">28,95,124</a>]. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a> and <a class="local">'Ciliary motion and ultrastructure'</a> above.)</p><p>Evidence in support of extended panel testing comes from studies that show increasing diagnostic sensitivity as the number of analyzed PCD genes increases [<a href="#rid45">45,95,127,128</a>]. As an example, among 205 children (age 0 to 18 years) who were thought to have definite PCD, a standard genetic panel identified 138 pathogenic variants, while an extended panel identified 26 additional genetic variants [<a href="#rid45">45</a>]. Approximately 35 percent of participants with "definite PCD" had pathogenic mutations in <em>DNAH5</em> or <em>DNAI1</em> [<a href="#rid45">45</a>]. Even extended panel testing has limitations; in this study, testing did not find genetic variants in 41 participants with "definite" PCD. </p><p class="headingAnchor" id="H992691174"><span class="h2">Measures of mucociliary transport</span><span class="headingEndMark"> — </span>Methods to assess mucociliary transport are limited by availability and difficulties with specificity and, thus, are infrequently used. Cilia from the airways may be immobilized by bacterial toxins; immotility is then acquired rather than inborn and is associated with a different prognosis. Furthermore, mucociliary transport involves a two-component system, and the abnormality may reside in the mucus rather than in the cilia. As an example, patients with cystic fibrosis generate very viscous mucus, which their normal cilia are unable to propel forward. Mucus from patients with asthma also is more viscous than in healthy persons.</p><p>One method for measuring mucociliary transport in situ is to administer an inhalation aerosol of colloid albumin tagged with 99Tc [<a href="#rid129">129-131</a>]. Radioactivity within the lungs is then measured repeatedly for two hours and again at 24 hours by profile scanning of the thorax while the patient is supine. The amount of coughing must be monitored for two hours, because coughing acts as a substitute for mucociliary clearance and results in elimination of the isotope from the lungs. This test can only be performed in adults and children over the age of five. In a large series of patients with primary ciliary dysfunction and those suspected of the disease, the test had high positive and negative predictive values compared with nasal ciliary function tests (eg, saccharin clearance). An absence of mucociliary clearance is a sign of ciliary immotility, dysmotility, or aplasia, which may be inborn or acquired.</p><p>A somewhat simpler, previously used technique, called nasal mucociliary clearance (NMCC), consists of depositing small particles of saccharin or dye in the concha inferior and measuring the time required for the taste of the marker to be perceived or the dye to become visible in the throat [<a href="#rid132">132,133</a>]. However, as mentioned above, these methods are associated with major disadvantages. A "positive" test result (NMCC &lt;60 minutes) is considered as inconsistent with PCD while a "negative" test result (NMCC &gt;60 minutes) is of no value. However, these techniques are less reliable than other methods of diagnosis and cannot be used in small children.</p><p class="headingAnchor" id="H26740130"><span class="h2">Other tests</span><span class="headingEndMark"> — </span>Other diagnostic tests have been proposed but have a less well-defined role. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>A gel electrophoretic examination of dyneins in a biopsy from the nasal epithelium or a sample of ejaculate [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using a dynein gene probe to map the corresponding messenger RNA in lung or testicular tissue [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examining whether spermatozoa are motile or immotile, although care must be taken to differentiate dead from living, but immotile, spermatozoa. It must also be kept in mind that occasional patients have immotile cilia but normally motile spermatozoa [<a href="#rid81">81</a>]. </p><p></p><p class="headingAnchor" id="H26740144"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The optimal management of the sequelae of PCD is not known, so recommendations are based in part on experience treating patients with cystic fibrosis and other forms of bronchiectasis. In general, treatment must be individualized depending upon the specific clinical course of a given patient [<a href="#rid4">4,65,136</a>]. </p><p class="headingAnchor" id="H1179080239"><span class="h2">Pneumonia without obvious bronchiectasis</span><span class="headingEndMark"> — </span>Infections in the lower respiratory tract need to be treated promptly to delay the development of bronchiectasis, which occurs in most patients with PCD. Based on our clinical experience, we follow an approach similar to that used in patients with cystic fibrosis (see  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Review the most recent sputum cultures and history of antibiotic use; obtain a new sputum sample for culture.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiate antibiotic treatment in patients with suspected pneumonia even when symptoms are mild, such as a sudden increase in the amount of colored sputum combined with a low fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Select empiric antibiotics that have activity against the pathogenic bacteria identified in the patient's most recent sputum cultures. The duration of antibiotics is generally 10 to 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway clearance therapy is typically intensified during treatment for pneumonia. (See <a class="local">'Bronchiectasis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess for clinical improvement within approximately four to five days of starting treatment. If not improving, and a bacterial infection is still likely, adjust the antibiotic regimen. Choose a new regimen either empirically or by adjusting the regimen if new culture results reveal a bacteria species not covered by the initial regimen.</p><p></p><p class="headingAnchor" id="H1644180693"><span class="h2">Bronchiectasis</span><span class="headingEndMark"> — </span>Clearing secretions and reducing the microbial load with selective use of antibiotics form the cornerstone of preventive therapy for PCD-related bronchiectasis as with bronchiectasis from other causes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Airway clearance</strong> <strong>therapy</strong> – Daily chest physiotherapy is important in compensating for diminished or absent mucociliary clearance, and a number of airway clearance techniques are available, as described separately. (See  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management", section on 'Airway clearance therapy'</a> and  <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Airway clearance therapy'</a>.)</p><p></p><p class="bulletIndent1">The effectiveness of airway hydration (eg, nebulized hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> [7 percent]) has not been fully assessed in PCD [<a href="#rid65">65,137,138</a>]. However, based on clinical experience and studies in noncystic fibrosis bronchiectasis, we typically add hypertonic saline twice daily to the routine airway clearance program in patients with recurrent respiratory infections or ongoing moderate or severe respiratory symptoms [<a href="#rid139">139-142</a>]. Inhaled bronchodilator is given prior to each treatment. The administration of hypertonic saline is described separately. (See  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management", section on 'Inhaled airway hydrating agents and mucolytics'</a> and  <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Mucolytic agents and airway hydration'</a>.)</p><p></p><p class="bulletIndent1">Of note, <a class="drug drug_general" data-topicid="9385" href="/z/d/drug information/9385.html" rel="external">DNase</a> has been found to be beneficial in cystic fibrosis but is not recommended in non-CF bronchiectasis. A role for mucolytic drugs (eg, <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">acetylcysteine</a>) has not been established [<a href="#rid138">138</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute exacerbations</strong> – Acute exacerbations of bronchiectasis due to bacterial infection are usually heralded by increased production of sputum that is more viscous and of darker color and may be accompanied by lassitude, shortness of breath, pleuritic chest pain, or hemoptysis, while fever may not be present. Such exacerbations are treated with oral antibiotics, even when the symptoms are mild. Regular sputum cultures should be obtained to identify resistant organisms and guide antibiotic therapy.</p><p></p><p class="bulletIndent1">Intravenous antibiotics may be required for treatment of <em>Pseudomonas aeruginosa</em> infection, or in cases of severe pneumonia from other bacterial etiologies [<a href="#rid136">136</a>]. Early and definitive treatment of respiratory infections may prevent or delay the evolution of bronchiectasis and minimize the progressive loss of lung function that is otherwise noted. The management of infection in noncystic fibrosis bronchiectasis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management"</a> and  <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent exacerbations</strong> – For patients with recurrent exacerbations who are ≥7 years of age, preventive antibiotic therapy (usually with a macrolide) may reduce the rate of exacerbations. <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> preventive therapy has shown benefit in cystic fibrosis and noncystic fibrosis bronchiectasis. In addition, a multinational randomized trial (BESTCILIA) in 90 participants with PCD (age 7 to 50 years) demonstrated that azithromycin maintenance therapy (250 mg for &lt;40 kg; 500 mg for ≥40 kg) three times a week for six months was well tolerated and halved the rate of respiratory exacerbations (rate ratio 0.45; 95% CI 0.26-0.78) [<a href="#rid143">143</a>].</p><p></p><p class="bulletIndent1">Alternatively, it is reasonable to defer initiation of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> and observe for additional exacerbations. Prior to initiating long-term antibiotic therapy, sputum cultures should be checked to exclude nontuberculous mycobacteria infection and patients should be assessed for risk of QT interval prolongation (eg, family history, other medications). The optimal duration of therapy is not known; it is reasonable to re-evaluate after six months. The potential benefits of chronic antibiotics in these patients must be balanced against the risk of developing antibiotic resistance. Referral to a specialist center is advisable in this situation. (See  <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Macrolides'</a>.)</p><p></p><p class="bulletIndent1">For patients with recurrent exacerbations and <em>Pseudomonas aeruginosa</em> in their sputum, a therapeutic trial of inhaled antipseudomonal antibiotics (eg, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>) is reasonable alone or in combination with a course of an antipseudomonal antibiotic aimed at early eradication. In one study of 31 children with PCD and new <em>Pseudomonas aeruginosa </em>infection, 97 percent achieved negative culture results, and 70 percent had prolonged (one year) pseudomonas eradication after treatment with inhaled tobramycin followed by intravenous therapy for persistent culture positivity [<a href="#rid144">144</a>]. Inhaled antibiotic therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Inhaled antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management", section on 'Chronic antibiotics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Age and season-appropriate vaccination against influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19), and pneumococcus is advisable. (See  <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a> and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>.)</p><p></p><p class="bulletIndent1">Smoking causes a more rapid deterioration in lung function, and counseling regarding abstinence from smoking is essential. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced disease</strong> – Surgical intervention to remove an isolated area of bronchiectasis is rarely recommended due to the risks of the procedure and likelihood of development of bronchiectasis in other areas [<a href="#rid145">145</a>]. For patients with advanced respiratory insufficiency, bilateral lung transplantation is preferred to single lung transplantation similar to bronchiectasis from other causes, although heart-lung transplantation or a modified surgical procedure is required in patients with situs inversus [<a href="#rid146">146-148</a>]. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/3525.html" rel="external">"Heart-lung transplantation in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1644180699"><span class="h2">Chronic rhinosinusitis and nasal polyposis</span><span class="headingEndMark"> — </span>While not specifically assessed in PCD, the medical management of chronic rhinosinusitis includes nasal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> lavage, intranasal glucocorticoids for nasal polyposis, and antibiotic therapy for exacerbations. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>Surgical interventions to treat chronic sinusitis and nasal polyposis may be necessary in a subset of patients. Indications for functional endoscopic sinus surgery include debulking of severe polyposis, failure of intensive medical management, bony erosion due to chronic infection, or extension of disease beyond the sinus cavities, as described separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Surgical management'</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H5103375"><span class="h2">Otitis media with effusion</span><span class="headingEndMark"> — </span>Chronic otitis media with effusion (OME) is common in children and adolescents with PCD (&gt;80 percent) and can lead to hearing loss [<a href="#rid139">139,149</a>]. While the value of pressure equalization tubes (PET, also called tympanostomy tubes) in chronic OME has been questioned [<a href="#rid65">65,71,150</a>], consensus guidelines from the PCD Foundation advise use of PET in patients with hearing deficits or speech delay because of the persistent nature of OME in these patients [<a href="#rid139">139,151,152</a>]. PET appear to improve hearing with normalization in 80 to 100 percent of patients, at least temporarily [<a href="#rid139">139,152,153</a>]. The general management of OME and the decision about PET placement are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management", section on 'Tympanostomy tubes'</a>.)</p><p>Conductive hearing loss and potential associated speech delays should be assessed regularly and hearing aids prescribed as required [<a href="#rid71">71,139</a>]. (See  <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>.)</p><p class="headingAnchor" id="H1644180837"><span class="h2">Impaired fertility</span><span class="headingEndMark"> — </span>Because ciliary immotility (or dysmotility) commonly is associated with abnormal sperm motility, male patients should be informed about possible infertility, and semen analysis should be offered. In vitro fertilization techniques, particularly intracytoplasmic sperm injection, have been effective in this setting [<a href="#rid154">154</a>]. (See  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7452.html" rel="external">"Treatments for male infertility"</a>.)</p><p>Female patients of child-bearing age should be alerted to the possibility of reduced fertility and the extremely rare risk of ectopic pregnancy. (See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation"</a>.)</p><p class="headingAnchor" id="H79261613"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Close, ongoing clinical follow-up is essential in PCD. We perform spirometry at every visit, starting at age six. Although evidence for this is lacking, we believe that it is useful to obtain an objective measure of lung function and a decrease in forced expiratory volume in one second (FEV<sub>1</sub>) may occasionally detect a subclinical exacerbation. On average, patients undergo spirometry one to three times a year. In contrast to its use in cystic fibrosis, the Lung Clearance Index (LCI) does not appear at this time to be a sensitive test of airway disease in advanced PCD [<a href="#rid64">64</a>].</p><p>Chest radiographs are relatively insensitive measures of bronchiectasis but may be helpful to evaluate changes in respiratory symptoms when compared with previous examinations. Longitudinal decreases in nasal nitric oxide levels, but not fractional exhaled nitric oxide levels, appear to correlate with lung function decline and increased risk of infections in some high-risk genotypes [<a href="#rid155">155</a>].</p><p>High-resolution computed tomography (HRCT) is more sensitive than conventional chest radiographs for detecting early airway and parenchymal lung changes. It is typically performed to evaluate worsening symptoms or abnormalities on chest radiograph that do not respond to initial therapy. As early recognition of deterioration (eg, mucus plugging, atelectasis, pneumonia) is important in patients with PCD, HRCT may be helpful in selected cases (eg, unexplained clinical deterioration, decline in spirometric values, or to determine the extent of bronchiectasis) [<a href="#rid60">60</a>].</p><p>The utility of HRCT for monitoring progression of lung disease was compared with spirometry in a retrospective study of 20 patients followed for a median interval of 2.3 years (range 1.3 to 3.4 years) [<a href="#rid156">156</a>]. HRCT scans significantly worsened over time, showing an increased extent of bronchiectasis, mucus plugging, peribronchial thickening, parenchymal abnormalities, and mosaic attenuation, while spirometry remained stable. This discrepancy between HRCT and spirometry (FEV<sub>1</sub>) seems to be more attenuated in patients with PCD compared to those with CF [<a href="#rid64">64</a>]. While HRCT appears more sensitive than spirometry, we do not obtain HRCT for routine monitoring due to concerns about radiation exposure. However, when performing an HRCT, it is a good idea to do a chest x-ray simultaneously making the interpretation of subsequent chest radiographs more reliable.</p><p class="headingAnchor" id="H26740151"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Persons with primary ciliary dyskinesia generally live an active life and have a normal lifespan. The rate of decline of lung function is much slower than with cystic fibrosis [<a href="#rid16">16,62</a>]. However, repeated or chronic infections, eg, sinusitis, may be tiresome and influence the ability to work full time. Moreover, the overall prognosis may relate to the specific gene and/or associated ultrastructural defect [<a href="#rid16">16</a>].</p><p>The effect of PCD on lung function was evaluated in a three-decade-long observational study [<a href="#rid62">62</a>]. Seventy-four patients underwent interval pulmonary function testing over a median of 9.5 (range, 1.5 to 30.2) years. The cohort consisted mostly of children and young adults; the smoking history of these patients was not reported. There was a high degree of variation in the course of lung function after diagnosis. During the observation period, approximately 60 percent had a stable forced expiratory volume in one second (FEV<sub>1</sub>), 30 percent had a decrease of more than 10 percent, and 10 percent had a greater than 10 percent improvement. The variation in lung function was not related to age or level of lung function at the time of diagnosis.</p><p>Other studies have assessed clinical course in children and young adults to determine risk factors for more severe disease. In one multinational retrospective cohort of 486 patients between the ages of 6 and 24 years, there was a trend towards decreased lung function over time (FEV<sub>1</sub> z-score change of -0.07 per year), but there was a large amount of heterogeneity in disease course between countries and between individuals [<a href="#rid157">157</a>]. Higher BMI was associated with better baseline lung function and less decline. Different ultrastructural defects were associated with low baseline FEV<sub>1</sub> levels versus longitudinal worsening, with combined outer and inner dynein arm defects showing the highest rate of FEV<sub>1</sub> decline. In a separate prospective five-year study of 137 patients with PCD (age ≤19 years), those with variants leading to absent inner dynein arm, central apparatus defects, and microtubular disorganization, including individuals with CCDC39 and CCDC40 mutations, had lower growth indices and worse lung function compared with participants with outer dynein arm defects and DNAH5 mutations [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H26814682"><span class="h1">ADDITIONAL RESOURCES</span><span class="headingEndMark"> — </span>An international registry for patients with PCD has been established [<a href="#rid158">158</a>].</p><p>Information about clinical research sites for patients with PCD is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgdmcc.rarediseasesnetwork.org%2Fdiseases-studied%23PCD&amp;token=TB%2FS7TlxYUYfJJiRPKaqDCM4nobopx5KElbj7ZWKLOqhzMQBCQFhw3c26ILK4ryHFHCIzJT9vAiuEtfBE5KZYg%3D%3D&amp;TOPIC_ID=4338" target="_blank">Rare Diseases Clinical Research Network</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpcdsupport.org.uk%2F&amp;token=XviRtefpZpMmq89pNY0%2FH%2Fjh%2F7Q9SRGoi9hmtPYSyKgF%2F9QxdOYsbXm8cohwJXz1&amp;TOPIC_ID=4338" target="_blank">PCD Family Support Group (UK)</a>.</p><p>Additional information for patients and families can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpcdfoundation.org%2F&amp;token=7ljnpkTKHjlBn75%2Bm800%2FzcT1ReY%2FPMwC92oC9aujwLaabWeB2ZFJjjYqaOi%2BCeb&amp;TOPIC_ID=4338" target="_blank">PCD Foundation</a> website.</p><p class="headingAnchor" id="H349533338"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122199.html" rel="external">"Society guideline links: Primary ciliary dyskinesia"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116208.html" rel="external">"Society guideline links: Bronchiectasis"</a>.)</p><p class="headingAnchor" id="H26740158"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Primary ciliary dyskinesia (PCD), also called the immotile-cilia syndrome, includes patients with a spectrum of ciliary abnormalities, including ciliary akinesia, dyskinesia, and aplasia. It is characterized by chronic cough, bronchiectasis, chronic rhinosinusitis, and recurrent otitis media  (<a class="graphic graphic_diagnosticimage graphicRef89096" href="/z/d/graphic/89096.html" rel="external">image 2</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – The inheritance pattern of PCD is autosomal recessive in most cases. A number of different PCD-causing mutations have been described, including mutations in the axonemal outer dynein arms (<em>DNAH5, DNAH9, DNAH12, DNAI1</em>), inner dynein arms (<em>DNALI1</em>), assembly proteins (<em>DNAAF3</em>), and radial spokes (<em>RSPH4A, RSPH9</em>). Situs inversus is present in about 50 percent of individuals with PCD. (See <a class="local">'Genetics'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – A combination of tests is necessary for accurate diagnosis of PCD  (<a class="graphic graphic_algorithm graphicRef114172" href="/z/d/graphic/114172.html" rel="external">algorithm 1</a>). A history of neonatal respiratory distress, early onset and persistent productive cough, chronic nasal congestion and rhinorrhea, chronic otitis media, and/or a laterality defect (eg, situs inversus or ambiguous) should raise a strong clinical suspicion for PCD in the absence of cystic fibrosis or prematurity  (<a class="graphic graphic_table graphicRef132458" href="/z/d/graphic/132458.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Measuring the production of nasal nitric oxide (nNO) is a useful method to screen patients age five years or older with a clinical suspicion of PCD. Mucociliary clearance, another screening test, is not standardized, and the saccharin clearance time is not reliable. Semen analysis is an option in adult males. At present, none of these tests is diagnostic, so a confirmatory test is necessary. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitive diagnosis</strong> – Definitive diagnosis is usually based on identification of ciliary abnormalities on high speed videomicroscopy analysis (HSVA) or transmission electron microscopy (TEM). These tests require nasal or bronchial biopsy and are only available at specialized centers with expertise in these tests. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If HSVA is abnormal or equivocal, TEM is used to visualize specific defects, such as absence of dynein arms or radial spokes and absent, or additional, microtubule assemblies  (<a class="graphic graphic_table graphicRef128206" href="/z/d/graphic/128206.html" rel="external">table 3</a>). (See <a class="local">'Ciliary motion and ultrastructure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing has an increasing role in PCD diagnosis, particularly when extended panel testing (&gt;12 genes) is available. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reducing respiratory infections </strong>– Interventions to improve secretion clearance and reduce respiratory infections include daily chest physiotherapy and prompt treatment of respiratory infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with recurrent respiratory infections or ongoing moderate or severe respiratory symptoms, we suggest regular use of nebulized (hypertonic) <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatments are given twice daily before airway clearance techniques; inhaled bronchodilator is administered prior to nebulized saline. A role for mucolytic drugs has not been established. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management"</a> and  <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients 7 years of age and older with frequent exacerbations of bronchiectasis (eg, requiring antibiotics for at least 30 days in prior two years), we suggest <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> maintenance therapy (250 mg for &lt;40 kg or 500 mg for ≥40 kg, three times a week) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Alternatively, for patients with less severe baseline bronchiectasis, it is reasonable to observe and provide antibiotics as needed for flares of bronchiectasis. Infection with nontuberculous mycobacteria should be excluded prior to initiating azithromycin. (See <a class="local">'Bronchiectasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated problems</strong> – Patients with PCD often have chronic otitis media with effusion (OME), recurrent episodes of acute otitis media, and concomitant hearing loss. The placement of pressure equalization tubes (PET, also called tympanostomy tubes) is often appropriate in patients with hearing loss and/or speech delay due to chronic OME and is discussed in detail separately. (See <a class="local">'Otitis media with effusion'</a> above and  <a class="medical medical_review" href="/z/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management", section on 'Tympanostomy tubes'</a>.)</p><p></p><p class="bulletIndent1">Rhinosinusitis is a cardinal feature of PCD, occurring in almost 100 percent of affected individuals, often with associated nasal polyposis; the management follows standard practices for chronic rhinosinusitis with nasal polyposis. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">Because ciliary immotility (or dysmotility) is commonly associated with abnormal sperm motility, male patients should be informed about possible infertility and offered semen analysis. Female patients with PCD may also have reduced fertility. In vitro fertilization techniques, particularly intracytoplasmic sperm injection, have been effective in this setting. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Smoking causes a more rapid deterioration in lung function, and counseling regarding abstinence from smoking is essential. Age and season-appropriate vaccination against influenza and pneumococcus is advised. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – Persons with primary ciliary dyskinesia generally live an active life and have a normal lifespan. The rate of decline of lung function is much slower than with cystic fibrosis. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Afzelius BA. A human syndrome caused by immotile cilia. Science 1976; 193:317.</a></li><li class="breakAll">Afzelius BA, Mossberg B, Bergström SE. Immotile-cilia syndrome (primary ciliary dyskinesia) including Kartagener syndrome. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Vale D (Eds), McGraw Hill, New York 2000.</li><li><a class="nounderline abstract_t">Afzelius BA, Stenram U. Prevalence and genetics of immotile-cilia syndrome and left-handedness. Int J Dev Biol 2006; 50:571.</a></li><li><a class="nounderline abstract_t">Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 188:913.</a></li><li><a class="nounderline abstract_t">Horani A, Ferkol TW. Understanding Primary Ciliary Dyskinesia and Other Ciliopathies. J Pediatr 2021; 230:15.</a></li><li><a class="nounderline abstract_t">Hannah WB, Seifert BA, Truty R, et al. The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis. Lancet Respir Med 2022; 10:459.</a></li><li><a class="nounderline abstract_t">Pioch CO, Connell DW, Shoemark A. Primary Ciliary Dyskinesia and Bronchiectasis: New Data and Future Challenges. Arch Bronconeumol 2023; 59:134.</a></li><li><a class="nounderline abstract_t">Rosenbaum JL, Cole DG, Diener DR. Intraflagellar transport: the eyes have it. J Cell Biol 1999; 144:385.</a></li><li><a class="nounderline abstract_t">Merveille AC, Davis EE, Becker-Heck A, et al. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. Nat Genet 2011; 43:72.</a></li><li><a class="nounderline abstract_t">Becker-Heck A, Zohn IE, Okabe N, et al. The coiled-coil domain containing protein CCDC40 is essential for motile cilia function and left-right axis formation. Nat Genet 2011; 43:79.</a></li><li><a class="nounderline abstract_t">Mitchison HM, Schmidts M, Loges NT, et al. Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia. Nat Genet 2012; 44:381.</a></li><li><a class="nounderline abstract_t">Boon M, Jorissen M, Proesmans M, De Boeck K. Primary ciliary dyskinesia, an orphan disease. Eur J Pediatr 2013; 172:151.</a></li><li><a class="nounderline abstract_t">Ferkol TW, Puffenberger EG, Lie H, et al. Primary ciliary dyskinesia-causing mutations in Amish and Mennonite communities. J Pediatr 2013; 163:383.</a></li><li><a class="nounderline abstract_t">Vallet C, Escudier E, Roudot-Thoraval F, et al. Primary ciliary dyskinesia presentation in 60 children according to ciliary ultrastructure. Eur J Pediatr 2013; 172:1053.</a></li><li><a class="nounderline abstract_t">Davis SD, Ferkol TW, Rosenfeld M, et al. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med 2015; 191:316.</a></li><li><a class="nounderline abstract_t">Davis SD, Rosenfeld M, Lee HS, et al. Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. Am J Respir Crit Care Med 2019; 199:190.</a></li><li><a class="nounderline abstract_t">Zariwala MA, Knowles MR, Omran H. Genetic defects in ciliary structure and function. Annu Rev Physiol 2007; 69:423.</a></li><li><a class="nounderline abstract_t">Wallmeier J, Frank D, Shoemark A, et al. De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry. Am J Hum Genet 2019; 105:1030.</a></li><li><a class="nounderline abstract_t">Paff T, Loges NT, Aprea I, et al. Mutations in PIH1D3 Cause X-Linked Primary Ciliary Dyskinesia with Outer and Inner Dynein Arm Defects. Am J Hum Genet 2017; 100:160.</a></li><li><a class="nounderline abstract_t">Narayan D, Krishnan SN, Upender M, et al. Unusual inheritance of primary ciliary dyskinesia (Kartagener's syndrome). J Med Genet 1994; 31:493.</a></li><li><a class="nounderline abstract_t">Zariwala MA, Omran H, Ferkol TW. The emerging genetics of primary ciliary dyskinesia. Proc Am Thorac Soc 2011; 8:430.</a></li><li class="breakAll">Online Mendelian Inheritance in Man. Ciliary dyskinesia, primary. http://omim.org/entry/244400 (Accessed on January 07, 2014).</li><li><a class="nounderline abstract_t">Horani A, Brody SL, Ferkol TW. Picking up speed: advances in the genetics of primary ciliary dyskinesia. Pediatr Res 2014; 75:158.</a></li><li><a class="nounderline abstract_t">Lucas JS, Burgess A, Mitchison HM, et al. Diagnosis and management of primary ciliary dyskinesia. Arch Dis Child 2014; 99:850.</a></li><li><a class="nounderline abstract_t">Knowles MR, Ostrowski LE, Leigh MW, et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med 2014; 189:707.</a></li><li><a class="nounderline abstract_t">Kurkowiak M, Ziętkiewicz E, Witt M. Recent advances in primary ciliary dyskinesia genetics. J Med Genet 2015; 52:1.</a></li><li><a class="nounderline abstract_t">Raidt J, Wallmeier J, Hjeij R, et al. Ciliary beat pattern and frequency in genetic variants of primary ciliary dyskinesia. Eur Respir J 2014; 44:1579.</a></li><li><a class="nounderline abstract_t">Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Guo Z, Chen W, Wang L, Qian L. Clinical and Genetic Spectrum of Children with Primary Ciliary Dyskinesia in China. J Pediatr 2020; 225:157.</a></li><li class="breakAll">OMIM - Online Mendelian Inheritance in Man. Primary ciliary dyskinesia - PS244400 - Phenotypic Series. https://www.omim.org/phenotypicSeries/PS244400 (Accessed on July 12, 2021).</li><li><a class="nounderline abstract_t">Poplawska K, Griffiths A, Temme R, et al. Deletions in DNAL1 Cause Primary Ciliary Dyskinesia Across North American Indigenous Populations. J Pediatr 2023; 261:113362.</a></li><li><a class="nounderline abstract_t">Pennarun G, Escudier E, Chapelin C, et al. Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia. Am J Hum Genet 1999; 65:1508.</a></li><li><a class="nounderline abstract_t">Olbrich H, Häffner K, Kispert A, et al. Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry. Nat Genet 2002; 30:143.</a></li><li><a class="nounderline abstract_t">Hornef N, Olbrich H, Horvath J, et al. DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. Am J Respir Crit Care Med 2006; 174:120.</a></li><li><a class="nounderline abstract_t">Fliegauf M, Olbrich H, Horvath J, et al. Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. Am J Respir Crit Care Med 2005; 171:1343.</a></li><li><a class="nounderline abstract_t">Morillas HN, Zariwala M, Knowles MR. Genetic causes of bronchiectasis: primary ciliary dyskinesia. Respiration 2007; 74:252.</a></li><li><a class="nounderline abstract_t">Duriez B, Duquesnoy P, Escudier E, et al. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. Proc Natl Acad Sci U S A 2007; 104:3336.</a></li><li><a class="nounderline abstract_t">Loges NT, Olbrich H, Fenske L, et al. DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm. Am J Hum Genet 2008; 83:547.</a></li><li><a class="nounderline abstract_t">Schwabe GC, Hoffmann K, Loges NT, et al. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations. Hum Mutat 2008; 29:289.</a></li><li><a class="nounderline abstract_t">Hunter-Schouela J, Geraghty MT, Hegele RA, et al. First reports of primary ciliary dyskinesia caused by a shared DNAH11 allele in Canadian Inuit. Pediatr Pulmonol 2023; 58:1942.</a></li><li><a class="nounderline abstract_t">Castleman VH, Romio L, Chodhari R, et al. Mutations in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary dyskinesia with central-microtubular-pair abnormalities. Am J Hum Genet 2009; 84:197.</a></li><li><a class="nounderline abstract_t">Leigh MW, Zariwala MA, Knowles MR. Primary ciliary dyskinesia: improving the diagnostic approach. Curr Opin Pediatr 2009; 21:320.</a></li><li><a class="nounderline abstract_t">Tan SY, Rosenthal J, Zhao XQ, et al. Heterotaxy and complex structural heart defects in a mutant mouse model of primary ciliary dyskinesia. J Clin Invest 2007; 117:3742.</a></li><li><a class="nounderline abstract_t">Noone PG, Bali D, Carson JL, et al. Discordant organ laterality in monozygotic twins with primary ciliary dyskinesia. Am J Med Genet 1999; 82:155.</a></li><li><a class="nounderline abstract_t">Leigh MW, Ferkol TW, Davis SD, et al. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Ann Am Thorac Soc 2016; 13:1305.</a></li><li><a class="nounderline abstract_t">Rubbo B, Best S, Hirst RA, et al. Clinical features and management of children with primary ciliary dyskinesia in England. Arch Dis Child 2020; 105:724.</a></li><li><a class="nounderline abstract_t">Cao Y, Shao C, Song Y, et al. Clinical analysis of patients with primary ciliary dyskinesia in mainland China. Clin Respir J 2016; 10:765.</a></li><li><a class="nounderline abstract_t">Kuehni CE, Frischer T, Strippoli MP, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J 2010; 36:1248.</a></li><li><a class="nounderline abstract_t">Yiallouros PK, Kouis P, Middleton N, et al. Clinical features of primary ciliary dyskinesia in Cyprus with emphasis on lobectomized patients. Respir Med 2015; 109:347.</a></li><li><a class="nounderline abstract_t">Nonaka S, Shiratori H, Saijoh Y, Hamada H. Determination of left-right patterning of the mouse embryo by artificial nodal flow. Nature 2002; 418:96.</a></li><li><a class="nounderline abstract_t">Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169:459.</a></li><li><a class="nounderline abstract_t">Lie H, Ferkol T. Primary ciliary dyskinesia: recent advances in pathogenesis, diagnosis and treatment. Drugs 2007; 67:1883.</a></li><li><a class="nounderline abstract_t">Lie H, Zariwala MA, Helms C, et al. Primary ciliary dyskinesia in Amish communities. J Pediatr 2010; 156:1023.</a></li><li><a class="nounderline abstract_t">Hosie PH, Fitzgerald DA, Jaffe A, et al. Presentation of primary ciliary dyskinesia in children: 30 years' experience. J Paediatr Child Health 2015; 51:722.</a></li><li><a class="nounderline abstract_t">Abitbul R, Amirav I, Blau H, et al. Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practices. Respir Med 2016; 119:41.</a></li><li><a class="nounderline abstract_t">Chapelin C, Coste A, Reinert P, et al. Incidence of primary ciliary dyskinesia in children with recurrent respiratory diseases. Ann Otol Rhinol Laryngol 1997; 106:854.</a></li><li><a class="nounderline abstract_t">Armengot-Carceller M, Reula A, Mata-Roig M, et al. Understanding Primary Ciliary Dyskinesia: Experience From a Mediterranean Diagnostic Reference Centre. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Santamaria F, Montella S, Tiddens HAWM, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008; 134:351.</a></li><li><a class="nounderline abstract_t">Nadel HR, Stringer DA, Levison H, et al. The immotile cilia syndrome: radiological manifestations. Radiology 1985; 154:651.</a></li><li><a class="nounderline abstract_t">Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007; 188:1232.</a></li><li><a class="nounderline abstract_t">Homma S, Kawabata M, Kishi K, et al. Bronchiolitis in Kartagener's syndrome. Eur Respir J 1999; 14:1332.</a></li><li><a class="nounderline abstract_t">Marthin JK, Petersen N, Skovgaard LT, Nielsen KG. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181:1262.</a></li><li><a class="nounderline abstract_t">Ring AM, Buchvald FF, Holgersen MG, et al. Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis. Respir Med 2018; 139:79.</a></li><li><a class="nounderline abstract_t">Irving SJ, Ives A, Davies G, et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med 2013; 188:545.</a></li><li><a class="nounderline abstract_t">Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009; 34:1264.</a></li><li><a class="nounderline abstract_t">Leigh MW, Pittman JE, Carson JL, et al. Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. Genet Med 2009; 11:473.</a></li><li><a class="nounderline abstract_t">Pifferi M, Bush A, Caramella D, et al. Agenesis of paranasal sinuses and nasal nitric oxide in primary ciliary dyskinesia. Eur Respir J 2011; 37:566.</a></li><li><a class="nounderline abstract_t">Bequignon E, Dupuy L, Zerah-Lancner F, et al. Critical Evaluation of Sinonasal Disease in 64 Adults with Primary Ciliary Dyskinesia. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Frija-Masson J, Bassinet L, Honoré I, et al. Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. Thorax 2017; 72:154.</a></li><li><a class="nounderline abstract_t">Plantier DB, Pilan RRM, Athanazio R, et al. Computed Tomography Evaluation of the Paranasal Sinuses in Adults with Primary Ciliary Dyskinesia. Int Arch Otorhinolaryngol 2023; 27:e130.</a></li><li><a class="nounderline abstract_t">Prulière-Escabasse V, Coste A, Chauvin P, et al. Otologic features in children with primary ciliary dyskinesia. Arch Otolaryngol Head Neck Surg 2010; 136:1121.</a></li><li><a class="nounderline abstract_t">Majithia A, Fong J, Hariri M, Harcourt J. Hearing outcomes in children with primary ciliary dyskinesia--a longitudinal study. Int J Pediatr Otorhinolaryngol 2005; 69:1061.</a></li><li><a class="nounderline abstract_t">Postema MC, Carrion-Castillo A, Fisher SE, et al. The genetics of situs inversus without primary ciliary dyskinesia. Sci Rep 2020; 10:3677.</a></li><li><a class="nounderline abstract_t">TORGERSEN J. Transposition of viscera, bronchiectasis and nasal polyps; a genetical analysis and a contribution to the problem of constitution. Acta radiol 1947; 28:17.</a></li><li><a class="nounderline abstract_t">Greenstone MA, Jones RW, Dewar A, et al. Hydrocephalus and primary ciliary dyskinesia. Arch Dis Child 1984; 59:481.</a></li><li><a class="nounderline abstract_t">Picco P, Leveratto L, Cama A, et al. Immotile cilia syndrome associated with hydrocephalus and precocious puberty: a case report. Eur J Pediatr Surg 1993; 3 Suppl 1:20.</a></li><li><a class="nounderline abstract_t">De Santi MM, Magni A, Valletta EA, et al. Hydrocephalus, bronchiectasis, and ciliary aplasia. Arch Dis Child 1990; 65:543.</a></li><li><a class="nounderline abstract_t">Berlucchi M, de Santi MM, Bertoni E, et al. Ciliary aplasia associated with hydrocephalus: an extremely rare occurrence. Eur Arch Otorhinolaryngol 2012; 269:2295.</a></li><li><a class="nounderline abstract_t">Shapiro AJ, Kaspy K, Daniels MLA, et al. Autosomal dominant variants in FOXJ1 causing primary ciliary dyskinesia in two patients with obstructive hydrocephalus. Mol Genet Genomic Med 2021; 9:e1726.</a></li><li><a class="nounderline abstract_t">Lee L. Riding the wave of ependymal cilia: genetic susceptibility to hydrocephalus in primary ciliary dyskinesia. J Neurosci Res 2013; 91:1117.</a></li><li><a class="nounderline abstract_t">Jonsson MS, McCormick JR, Gillies CG, Gondos B. Kartagener's syndrome with motile spermatozoa. N Engl J Med 1982; 307:1131.</a></li><li><a class="nounderline abstract_t">Munro NC, Currie DC, Lindsay KS, et al. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection. Thorax 1994; 49:684.</a></li><li><a class="nounderline abstract_t">Greenstone M, Rutman A, Dewar A, et al. Primary ciliary dyskinesia: cytological and clinical features. Q J Med 1988; 67:405.</a></li><li><a class="nounderline abstract_t">Schreck LD, Goutaki M, Jörger P, et al. Fertility care among people with primary ciliary dyskinesia. Pediatr Pulmonol 2024; 59:281.</a></li><li><a class="nounderline abstract_t">Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation 2007; 115:2814.</a></li><li><a class="nounderline abstract_t">Raman R, Al-Ali SY, Poole CA, et al. Isomerism of the right atrial appendages: clinical, anatomical, and microscopic study of a long-surviving case with asplenia and ciliary abnormalities. Clin Anat 2003; 16:269.</a></li><li><a class="nounderline abstract_t">Engesaeth VG, Warner JO, Bush A. New associations of primary ciliary dyskinesia syndrome. Pediatr Pulmonol 1993; 16:9.</a></li><li><a class="nounderline abstract_t">Simsek S, Inal-Ince D, Cakmak A, et al. Reduced anaerobic and aerobic performance in children with primary ciliary dyskinesia. Eur J Pediatr 2018; 177:765.</a></li><li><a class="nounderline abstract_t">Fırat M, Boşnak-Güçlü M, Şişmanlar-Eyüboğlu T, Aslan AT. Aerobic exercise capacity, cough strength, posture, and depression in primary ciliary dyskinesia. Pediatr Pulmonol 2023; 58:73.</a></li><li><a class="nounderline abstract_t">Madsen A, Green K, Buchvald F, et al. Aerobic fitness in children and young adults with primary ciliary dyskinesia. PLoS One 2013; 8:e71409.</a></li><li><a class="nounderline abstract_t">Boon M, De Boeck K, Jorissen M, Meyts I. Primary ciliary dyskinesia and humoral immunodeficiency--is there a missing link? Respir Med 2014; 108:931.</a></li><li><a class="nounderline abstract_t">Behan L, Dimitrov BD, Kuehni CE, et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016; 47:1103.</a></li><li><a class="nounderline abstract_t">Lobo LJ, Zariwala MA, Noone PG. Primary ciliary dyskinesia. QJM 2014; 107:691.</a></li><li><a class="nounderline abstract_t">Jackson CL, Behan L, Collins SA, et al. Accuracy of diagnostic testing in primary ciliary dyskinesia. Eur Respir J 2016; 47:837.</a></li><li><a class="nounderline abstract_t">Shapiro AJ, Davis SD, Polineni D, et al. Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 197:e24.</a></li><li><a class="nounderline abstract_t">Corbelli R, Bringolf-Isler B, Amacher A, et al. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004; 126:1054.</a></li><li><a class="nounderline abstract_t">Grasemann H, Gärtig SS, Wiesemann HG, et al. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 1999; 13:114.</a></li><li><a class="nounderline abstract_t">Horváth I, Loukides S, Wodehouse T, et al. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003; 58:68.</a></li><li><a class="nounderline abstract_t">Karadag B, James AJ, Gültekin E, et al. Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia. Eur Respir J 1999; 13:1402.</a></li><li><a class="nounderline abstract_t">Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. Eur Respir J 2011; 37:559.</a></li><li><a class="nounderline abstract_t">Leigh MW, Hazucha MJ, Chawla KK, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc 2013; 10:574.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912.</a></li><li><a class="nounderline abstract_t">Kouis P, Papatheodorou SI, Yiallouros PK. Diagnostic accuracy of nasal nitric oxide for establishing diagnosis of primary ciliary dyskinesia: a meta-analysis. BMC Pulm Med 2015; 15:153.</a></li><li><a class="nounderline abstract_t">Shapiro AJ, Josephson M, Rosenfeld M, et al. Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis. Ann Am Thorac Soc 2017; 14:1184.</a></li><li><a class="nounderline abstract_t">Beydon N, Kouis P, Marthin JK, et al. Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard. Eur Respir J 2023; 61.</a></li><li><a class="nounderline abstract_t">Shapiro AJ, Dell SD, Gaston B, et al. Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols. Ann Am Thorac Soc 2020; 17:e1.</a></li><li><a class="nounderline abstract_t">Raidt J, Krenz H, Tebbe J, et al. Limitations of Nasal Nitric Oxide Measurement for Diagnosis of Primary Ciliary Dyskinesia with Normal Ultrastructure. Ann Am Thorac Soc 2022; 19:1275.</a></li><li><a class="nounderline abstract_t">Boon M, Smits A, Cuppens H, et al. Primary ciliary dyskinesia: critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure. Orphanet J Rare Dis 2014; 9:11.</a></li><li><a class="nounderline abstract_t">Legendre M, Thouvenin G, Taytard J, et al. High Nasal Nitric Oxide, Cilia Analyses, and Genotypes in a Retrospective Cohort of Children with Primary Ciliary Dyskinesia. Ann Am Thorac Soc 2022; 19:1704.</a></li><li><a class="nounderline abstract_t">Walker WT, Jackson CL, Lackie PM, et al. Nitric oxide in primary ciliary dyskinesia. Eur Respir J 2012; 40:1024.</a></li><li><a class="nounderline abstract_t">Pifferi M, Bush A, Maggi F, et al. Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia. Eur Respir J 2011; 37:572.</a></li><li><a class="nounderline abstract_t">Csoma Z, Bush A, Wilson NM, et al. Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia. Chest 2003; 124:633.</a></li><li><a class="nounderline abstract_t">Jorissen M, Willems T, Van der Schueren B, et al. Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis in culture. Acta Otorhinolaryngol Belg 2000; 54:343.</a></li><li><a class="nounderline abstract_t">Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007; 92:1136.</a></li><li><a class="nounderline abstract_t">Jackson CL, Bottier M. Methods for the assessment of human airway ciliary function. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Jorissen M, Willems T, Van der Schueren B. Ciliary function analysis for the diagnosis of primary ciliary dyskinesia: advantages of ciliogenesis in culture. Acta Otolaryngol 2000; 120:291.</a></li><li><a class="nounderline abstract_t">Chilvers MA, Rutman A, O'Callaghan C. Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. Thorax 2003; 58:333.</a></li><li><a class="nounderline abstract_t">Stannard WA, Chilvers MA, Rutman AR, et al. Diagnostic testing of patients suspected of primary ciliary dyskinesia. Am J Respir Crit Care Med 2010; 181:307.</a></li><li><a class="nounderline abstract_t">Papon JF, Coste A, Roudot-Thoraval F, et al. A 20-year experience of electron microscopy in the diagnosis of primary ciliary dyskinesia. Eur Respir J 2010; 35:1057.</a></li><li><a class="nounderline abstract_t">Shoemark A, Boon M, Brochhausen C, et al. International consensus guideline for reporting transmission electron microscopy results in the diagnosis of primary ciliary dyskinesia (BEAT PCD TEM Criteria). Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Stannard W, Rutman A, Wallis C, O'Callaghan C. Central microtubular agenesis causing primary ciliary dyskinesia. Am J Respir Crit Care Med 2004; 169:634.</a></li><li><a class="nounderline abstract_t">Escudier E, Couprie M, Duriez B, et al. Computer-assisted analysis helps detect inner dynein arm abnormalities. Am J Respir Crit Care Med 2002; 166:1257.</a></li><li><a class="nounderline abstract_t">Hirst RA, Jackson CL, Coles JL, et al. Culture of primary ciliary dyskinesia epithelial cells at air-liquid interface can alter ciliary phenotype but remains a robust and informative diagnostic aid. PLoS One 2014; 9:e89675.</a></li><li><a class="nounderline abstract_t">Lucas JS, Davis SD, Omran H, Shoemark A. Primary ciliary dyskinesia in the genomics age. Lancet Respir Med 2020; 8:202.</a></li><li><a class="nounderline abstract_t">Shoemark A, Moya E, Hirst RA, et al. High prevalence of CCDC103 p.His154Pro mutation causing primary ciliary dyskinesia disrupts protein oligomerisation and is associated with normal diagnostic investigations. Thorax 2018; 73:157.</a></li><li><a class="nounderline abstract_t">Djakow J, Kramná L, Dušátková L, et al. An effective combination of sanger and next generation sequencing in diagnostics of primary ciliary dyskinesia. Pediatr Pulmonol 2016; 51:498.</a></li><li><a class="nounderline abstract_t">Marshall CR, Scherer SW, Zariwala MA, et al. Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia. G3 (Bethesda) 2015; 5:1775.</a></li><li><a class="nounderline abstract_t">Kim RH, A Hall D, Cutz E, et al. The role of molecular genetic analysis in the diagnosis of primary ciliary dyskinesia. Ann Am Thorac Soc 2014; 11:351.</a></li><li><a class="nounderline abstract_t">Camner P, Mossberg B, Afzelius BA. Measurements of tracheobronchial clearance in patients with immotile-cilia syndrome and its value in differential diagnosis. Eur J Respir Dis Suppl 1983; 127:57.</a></li><li><a class="nounderline abstract_t">Marthin JK, Mortensen J, Pressler T, Nielsen KG. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest 2007; 132:966.</a></li><li><a class="nounderline abstract_t">De Boeck K, Proesmans M, Mortelmans L, et al. Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia. Thorax 2005; 60:414.</a></li><li><a class="nounderline abstract_t">Stanley P, MacWilliam L, Greenstone M, et al. Efficacy of a saccharin test for screening to detect abnormal mucociliary clearance. Br J Dis Chest 1984; 78:62.</a></li><li><a class="nounderline abstract_t">Canciani M, Barlocco EG, Mastella G, et al. The saccharin method for testing mucociliary function in patients suspected of having primary ciliary dyskinesia. Pediatr Pulmonol 1988; 5:210.</a></li><li><a class="nounderline abstract_t">Mencarelli C, Tiezzi A, Ruggiero P, et al. Heterogeneous localization of epitopes along axonemes of mammalian cilia. Biol Cell 1995; 83:179.</a></li><li><a class="nounderline abstract_t">Kastury K, Taylor WE, Shen R, et al. Complementary deoxyribonucleic acid cloning and characterization of a putative human axonemal dynein light chain gene. J Clin Endocrinol Metab 1997; 82:3047.</a></li><li><a class="nounderline abstract_t">Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 1997; 10:2376.</a></li><li><a class="nounderline abstract_t">ten Berge M, Brinkhorst G, Kroon AA, de Jongste JC. DNase treatment in primary ciliary dyskinesia--assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999; 27:59.</a></li><li><a class="nounderline abstract_t">Stafanger G, Garne S, Howitz P, et al. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988; 1:161.</a></li><li><a class="nounderline abstract_t">Shapiro AJ, Zariwala MA, Ferkol T, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol 2016; 51:115.</a></li><li><a class="nounderline abstract_t">Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106:661.</a></li><li><a class="nounderline abstract_t">Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74:1.</a></li><li><a class="nounderline abstract_t">Kobbernagel HE, Buchvald FF, Haarman EG, et al. Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2020; 8:493.</a></li><li><a class="nounderline abstract_t">Gatt D, Shaw M, Wee W, et al. Efficacy of Antibiotic Eradication Therapy of Early Pseudomonas aeruginosa Infection in Children with Primary Ciliary Dyskinesia. Ann Am Thorac Soc 2023; 20:854.</a></li><li><a class="nounderline abstract_t">Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest 1996; 109:1541.</a></li><li><a class="nounderline abstract_t">Gauthier JM, Takahashi T, Bierhals AJ, et al. Technical Considerations for Lung Transplantation in Kartagener's Syndrome. Ann Thorac Surg 2019; 107:e337.</a></li><li><a class="nounderline abstract_t">Wang B, Zhang X, Jiang W, et al. Double lung transplantation for end-stage Kartagener syndrome: a case report and literature review. J Thorac Dis 2020; 12:1588.</a></li><li><a class="nounderline abstract_t">Yamamoto H, Sugimoto S, Miyoshi K, et al. Lung transplantation for Kartagener syndrome: technical aspects and morphological adaptation of the transplanted lungs. Gen Thorac Cardiovasc Surg 2021; 69:588.</a></li><li><a class="nounderline abstract_t">el-Sayed Y, al-Sarhani A, al-Essa AR. Otological manifestations of primary ciliary dyskinesia. Clin Otolaryngol Allied Sci 1997; 22:266.</a></li><li><a class="nounderline abstract_t">Wallace IF, Berkman ND, Lohr KN, et al. Surgical treatments for otitis media with effusion: a systematic review. Pediatrics 2014; 133:296.</a></li><li><a class="nounderline abstract_t">Campbell R. Managing upper respiratory tract complications of primary ciliary dyskinesia in children. Curr Opin Allergy Clin Immunol 2012; 12:32.</a></li><li><a class="nounderline abstract_t">Wolter NE, Dell SD, James AL, Campisi P. Middle ear ventilation in children with primary ciliary dyskinesia. Int J Pediatr Otorhinolaryngol 2012; 76:1565.</a></li><li><a class="nounderline abstract_t">Hadfield PJ, Rowe-Jones JM, Bush A, Mackay IS. Treatment of otitis media with effusion in children with primary ciliary dyskinesia. Clin Otolaryngol Allied Sci 1997; 22:302.</a></li><li><a class="nounderline abstract_t">von Zumbusch A, Fiedler K, Mayerhofer A, et al. Birth of healthy children after intracytoplasmic sperm injection in two couples with male Kartagener's syndrome. Fertil Steril 1998; 70:643.</a></li><li><a class="nounderline abstract_t">Pifferi M, Boner AL, Gracci S, et al. Longitudinal Nitric Oxide Levels and Infections by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. Chest 2022; 162:1265.</a></li><li><a class="nounderline abstract_t">Maglione M, Bush A, Montella S, et al. Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT? Pediatr Pulmonol 2012; 47:498.</a></li><li><a class="nounderline abstract_t">Halbeisen FS, Pedersen ESL, Goutaki M, et al. Lung function from school age to adulthood in primary ciliary dyskinesia. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Werner C, Lablans M, Ataian M, et al. An international registry for primary ciliary dyskinesia. Eur Respir J 2016; 47:849.</a></li></ol></div><div id="topicVersionRevision">Topic 4338 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1084576" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A human syndrome caused by immotile cilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1084576" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A human syndrome caused by immotile cilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16741872" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence and genetics of immotile-cilia syndrome and left-handedness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796196" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33242470" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Understanding Primary Ciliary Dyskinesia and Other Ciliopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051411" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36639347" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary Ciliary Dyskinesia and Bronchiectasis: New Data and Future Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9971734" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intraflagellar transport: the eyes have it.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131972" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131974" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The coiled-coil domain containing protein CCDC40 is essential for motile cilia function and left-right axis formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22387996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mutations in axonemal dynein assembly factor DNAAF3 cause primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777640" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary ciliary dyskinesia, an orphan disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477994" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary ciliary dyskinesia-causing mutations in Amish and Mennonite communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571820" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Primary ciliary dyskinesia presentation in 60 children according to ciliary ultrastructure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25493340" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067075" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059358" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic defects in ciliary structure and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31630787" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28041644" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mutations in PIH1D3 Cause X-Linked Primary Ciliary Dyskinesia with Outer and Inner Dynein Arm Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8071978" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Unusual inheritance of primary ciliary dyskinesia (Kartagener's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926394" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The emerging genetics of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926394" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The emerging genetics of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24192704" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Picking up speed: advances in the genetics of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771309" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and management of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24568568" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25351953" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recent advances in primary ciliary dyskinesia genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25186273" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ciliary beat pattern and frequency in genetic variants of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27836958" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32502479" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical and Genetic Spectrum of Children with Primary Ciliary Dyskinesia in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32502479" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical and Genetic Spectrum of Children with Primary Ciliary Dyskinesia in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36841509" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Deletions in DNAL1 Cause Primary Ciliary Dyskinesia Across North American Indigenous Populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577904" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788826" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627867" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750039" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534128" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Genetic causes of bronchiectasis: primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17360648" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18950741" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18022865" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088965" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : First reports of primary ciliary dyskinesia caused by a shared DNAH11 allele in Canadian Inuit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200523" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mutations in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary dyskinesia with central-microtubular-pair abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300264" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary ciliary dyskinesia: improving the diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037990" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Heterotaxy and complex structural heart defects in a mutant mouse model of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9934981" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Discordant organ laterality in monozygotic twins with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27070726" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32156696" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical features and management of children with primary ciliary dyskinesia in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25764361" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical analysis of patients with primary ciliary dyskinesia in mainland China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530032" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Factors influencing age at diagnosis of primary ciliary dyskinesia in European children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25698650" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical features of primary ciliary dyskinesia in Cyprus with emphasis on lobectomized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12097914" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Determination of left-right patterning of the mouse embryo by artificial nodal flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14656747" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Primary ciliary dyskinesia: diagnostic and phenotypic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722956" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary ciliary dyskinesia: recent advances in pathogenesis, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20350728" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Primary ciliary dyskinesia in Amish communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510893" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Presentation of primary ciliary dyskinesia in children: 30 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692146" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary ciliary dyskinesia in Israel: Prevalence, clinical features, current diagnosis and management practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9342982" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence of primary ciliary dyskinesia in children with recurrent respiratory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32188167" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Understanding Primary Ciliary Dyskinesia: Experience From a Mediterranean Diagnostic Reference Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403663" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Structural and functional lung disease in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969467" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The immotile cilia syndrome: radiological manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449765" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High-resolution CT of patients with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10624763" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Bronchiolitis in Kartagener's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167855" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29858006" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23815669" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948909" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19606528" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650983" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Agenesis of paranasal sinuses and nasal nitric oxide in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31067752" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Critical Evaluation of Sinonasal Disease in 64 Adults with Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27382041" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36714901" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Computed Tomography Evaluation of the Paranasal Sinuses in Adults with Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079168" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Otologic features in children with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16005347" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hearing outcomes in children with primary ciliary dyskinesia--a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32111882" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The genetics of situs inversus without primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20295650" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Transposition of viscera, bronchiectasis and nasal polyps; a genetical analysis and a contribution to the problem of constitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6732280" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hydrocephalus and primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130140" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immotile cilia syndrome associated with hydrocephalus and precocious puberty: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2357097" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Hydrocephalus, bronchiectasis, and ciliary aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791471" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ciliary aplasia associated with hydrocephalus: an extremely rare occurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34132502" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Autosomal dominant variants in FOXJ1 causing primary ciliary dyskinesia in two patients with obstructive hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686703" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Riding the wave of ependymal cilia: genetic susceptibility to hydrocephalus in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6981769" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Kartagener's syndrome with motile spermatozoa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8066563" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Fertility in men with primary ciliary dyskinesia presenting with respiratory infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2975807" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Primary ciliary dyskinesia: cytological and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37933800" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fertility care among people with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515466" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12673825" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Isomerism of the right atrial appendages: clinical, anatomical, and microscopic study of a long-surviving case with asplenia and ciliary abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8414746" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : New associations of primary ciliary dyskinesia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29487997" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Reduced anaerobic and aerobic performance in children with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36114723" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aerobic exercise capacity, cough strength, posture, and depression in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977038" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Aerobic fitness in children and young adults with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768622" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Primary ciliary dyskinesia and humoral immunodeficiency--is there a missing link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917608" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652656" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26647444" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Accuracy of diagnostic testing in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29905515" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486363" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10836334" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511725" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445619" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20525709" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024753" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817806" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26634346" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diagnostic accuracy of nasal nitric oxide for establishing diagnosis of primary ciliary dyskinesia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28481653" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36822632" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31770003" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202559" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Limitations of Nasal Nitric Oxide Measurement for Diagnosis of Primary Ciliary Dyskinesia with Normal Ultrastructure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24450482" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Primary ciliary dyskinesia: critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35622418" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : High Nasal Nitric Oxide, Cilia Analyses, and Genotypes in a Retrospective Cohort of Children with Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22408195" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Nitric oxide in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273388" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907553" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11082771" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Ultrastructural expression of primary ciliary dyskinesia after ciliogenesis in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634184" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Primary ciliary dyskinesia: current state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35595315" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Methods for the assessment of human airway ciliary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603792" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Ciliary function analysis for the diagnosis of primary ciliary dyskinesia: advantages of ciliogenesis in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668798" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910612" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Diagnostic testing of patients suspected of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840971" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A 20-year experience of electron microscopy in the diagnosis of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32060067" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : International consensus guideline for reporting transmission electron microscopy results in the diagnosis of primary ciliary dyskinesia (BEAT PCD TEM Criteria).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982824" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Central microtubular agenesis causing primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12403696" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Computer-assisted analysis helps detect inner dynein arm abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586956" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Culture of primary ciliary dyskinesia epithelial cells at air-liquid interface can alter ciliary phenotype but remains a robust and informative diagnostic aid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31624012" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Primary ciliary dyskinesia in the genomics age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28790179" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : High prevalence of CCDC103 p.His154Pro mutation causing primary ciliary dyskinesia disrupts protein oligomerisation and is associated with normal diagnostic investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26228299" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : An effective combination of sanger and next generation sequencing in diagnostics of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26139845" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24498942" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The role of molecular genetic analysis in the diagnosis of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6604650" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Measurements of tracheobronchial clearance in patients with immotile-cilia syndrome and its value in differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646235" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860718" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691910" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Efficacy of a saccharin test for screening to detect abnormal mucociliary clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3237448" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The saccharin method for testing mucociliary function in patients suspected of having primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7549913" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Heterogeneous localization of epitopes along axonemes of mammalian cilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284741" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Complementary deoxyribonucleic acid cloning and characterization of a putative human axonemal dynein light chain gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9387968" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Longitudinal study of lung function in a cohort of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023793" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : DNase treatment in primary ciliary dyskinesia--assessment by nocturnal pulse oximetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3282911" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418604" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22349069" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33542057" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545985" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : British Thoracic Society Guideline for bronchiectasis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32380069" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36753426" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Efficacy of Antibiotic Eradication Therapy of Early Pseudomonas aeruginosa Infection in Children with Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8769508" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30612988" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Technical Considerations for Lung Transplantation in Kartagener's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32395296" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Double lung transplantation for end-stage Kartagener syndrome: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33026567" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Lung transplantation for Kartagener syndrome: technical aspects and morphological adaptation of the transplanted lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222635" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Otological manifestations of primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394689" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Surgical treatments for otitis media with effusion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157161" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Managing upper respiratory tract complications of primary ciliary dyskinesia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883987" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Middle ear ventilation in children with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9298603" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Treatment of otitis media with effusion in children with primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797091" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Birth of healthy children after intracytoplasmic sperm injection in two couples with male Kartagener's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35777446" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Longitudinal Nitric Oxide Levels and Infections by Ultrastructure and Genotype in Primary Ciliary Dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22006708" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35301251" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Lung function from school age to adulthood in primary ciliary dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26659107" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : An international registry for primary ciliary dyskinesia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
